Sign In
Buy GNPX
$0.720
-0.0153 (-2.08%)
At Close: Jun 03, 2026
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
06:17pm, Wednesday, 04'th Jan 2023 Benzinga
Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sl
Genprex boosts its diabetes gene therapy program with the license of additional technology from the University of Pittsburgh
09:16am, Thursday, 15'th Dec 2022
Genprex, Inc. (NASDAQ:GNPX) revealed that it has struck an agreement with the University of Pittsburgh for a worldwide, exclusive license to some patent applications and a worldwide, non-exclusive li
Genprex gets green light for continuation of dose escalation Phase 1 of Acclaim-1 Phase 1/2 clinical trial of REQORSA
08:27am, Wednesday, 14'th Dec 2022
Genprex, Inc. (NASDAQ:GNPX) has announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1
Genprex to Present at Upcoming December Investor Conference
08:15am, Friday, 02'nd Dec 2022
Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clini
Genprex to Present at Upcoming October Investor and Industry Conferences
07:45am, Friday, 07'th Oct 2022
Corporate and Clinical Presentations to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX
Genprex to Present at Upcoming September Investor Conference
08:15am, Thursday, 08'th Sep 2022
Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 8, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clin
Analysts at Noble Capital reiterate 'Outperform' rating and $5 price target on Genprex
11:06am, Tuesday, 16'th Aug 2022
Analysts at Noble Capital have reiterated an 'Outperform' rating and $5 price target on Genprex Inc which recently announced that the first cohort from its Phase 1/2 Acclaim-1 trial in non-small cell
Genprex announces US patent for REQORSA Immunogene Therapy in combination with immune checkpoint inhibitors to treat cancers
08:59am, Tuesday, 16'th Aug 2022
Genprex, Inc. (NASDAQ:GNPX) said the company has been issued a patent that covers using REQORSA Immunogene Therapy in conjunction with immune checkpoint inhibitors for lung cancer. Thomas Gallagher, s
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
07:28am, Tuesday, 16'th Aug 2022 Benzinga
Gainers
Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.
Liberty TripAdvisor Holdings, Inc. (NASDAQ: LT
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
04:05pm, Monday, 15'th Aug 2022 Benzinga
Gainers
Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New E
Genprex secures higher dose approval for REQORSA in combination with Tagrisso Phase 1 clinical trial
08:23am, Monday, 15'th Aug 2022
Genprex, Inc. (NASDAQ:GNPX) announced that the Safety Review Committee (SRC) has approved a continuation of the Acclaim-1 Phase 1/2 clinical trial of the company's lead drug candidate REQORSA in combi
Genprex to Present at Upcoming Investor Conference in May 2022
08:15am, Thursday, 19'th May 2022
Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 19, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clini
Genprex announces opening of patient enrollment for its Acclaim-2 clinical trial
09:54am, Thursday, 31'st Mar 2022
Genprex Inc said it has opened patient enrollment for its Acclaim-2 clinical trial evaluating the company's lead drug candidate, REQORSA Immunogene Therapy. Acclaim-2 is an open-label, multi-center P
This Biotech Company Has Cancer and Diabetes Treatments in Development
10:04pm, Monday, 31'st Jan 2022 The Street
Real Money''s Timothy Collins says Genprex has persevered in the face of successive setbacks.
4 ‘Must Watch’ Penny Stocks Making Big Moves After Latest News
07:25pm, Thursday, 27'th Jan 2022 PennyStocks
4 names for your penny stocks list this week.
The post 4 ‘Must Watch’ Penny Stocks Making Big Moves After Latest News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc
